A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2022-11, Vol.140 (Supplement 1), p.10170-10171
Hauptverfasser: Akhtar, Othman Salim, Hillengass, Jens, Lipe, Brea, Figel, Sheila A., Fenstermaker, Robert A., Ciesielski, Michael J., Lee, Kelvin P.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 10171
container_issue Supplement 1
container_start_page 10170
container_title Blood
container_volume 140
creator Akhtar, Othman Salim
Hillengass, Jens
Lipe, Brea
Figel, Sheila A.
Fenstermaker, Robert A.
Ciesielski, Michael J.
Lee, Kelvin P.
description
doi_str_mv 10.1182/blood-2022-163597
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_163597</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122061274</els_id><sourcerecordid>S0006497122061274</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1857-37aef79593acbada2eb6f79dc659e475b5aab2e04835907340eb421f4a00a0d73</originalsourceid><addsrcrecordid>eNp9kN1O4zAQha0VSNvt8gDc-QE2y9iJ40Z7hRA_1bYsgsJtNLEnrZETV0lalNfhSdelXHM1mjk6c2Y-xs4F_BZiJi8qH4JNJEiZiDxVhf7GJkLJWQIg4YRNACBPskKL7-xH378CiCyVasLeL_nDBnvic_407OzIQ82fsKZh_MVXwVOHlfNuGDm2ls-bZtcGH9bOoOfXdU1m6D8cL_cqTXJ9sVQ6-bu4467lDzg4aqP-5oYNX-784Lae-HIkHxrkj2TI7V275gtq0TsbGmejjK4d4qA1xFebGL8df7LTGn1PZ591yp5vrldXd8ni3-386nKRGDGLsalGqnWhihRNhRYlVXnsrclVQZlWlUKsJEE2i3hApxlQlUlRZwiAYHU6ZeK413Sh7zuqy23nGuzGUkB5gFx-QC4PkMsj5Oj5c_RQPGzvqCt7E782ZF0X4ZQ2uC_c_wG6A4XI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Akhtar, Othman Salim ; Hillengass, Jens ; Lipe, Brea ; Figel, Sheila A. ; Fenstermaker, Robert A. ; Ciesielski, Michael J. ; Lee, Kelvin P.</creator><creatorcontrib>Akhtar, Othman Salim ; Hillengass, Jens ; Lipe, Brea ; Figel, Sheila A. ; Fenstermaker, Robert A. ; Ciesielski, Michael J. ; Lee, Kelvin P.</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-163597</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.10170-10171</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1857-37aef79593acbada2eb6f79dc659e475b5aab2e04835907340eb421f4a00a0d73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Akhtar, Othman Salim</creatorcontrib><creatorcontrib>Hillengass, Jens</creatorcontrib><creatorcontrib>Lipe, Brea</creatorcontrib><creatorcontrib>Figel, Sheila A.</creatorcontrib><creatorcontrib>Fenstermaker, Robert A.</creatorcontrib><creatorcontrib>Ciesielski, Michael J.</creatorcontrib><creatorcontrib>Lee, Kelvin P.</creatorcontrib><title>A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kN1O4zAQha0VSNvt8gDc-QE2y9iJ40Z7hRA_1bYsgsJtNLEnrZETV0lalNfhSdelXHM1mjk6c2Y-xs4F_BZiJi8qH4JNJEiZiDxVhf7GJkLJWQIg4YRNACBPskKL7-xH378CiCyVasLeL_nDBnvic_407OzIQ82fsKZh_MVXwVOHlfNuGDm2ls-bZtcGH9bOoOfXdU1m6D8cL_cqTXJ9sVQ6-bu4467lDzg4aqP-5oYNX-784Lae-HIkHxrkj2TI7V275gtq0TsbGmejjK4d4qA1xFebGL8df7LTGn1PZ591yp5vrldXd8ni3-386nKRGDGLsalGqnWhihRNhRYlVXnsrclVQZlWlUKsJEE2i3hApxlQlUlRZwiAYHU6ZeK413Sh7zuqy23nGuzGUkB5gFx-QC4PkMsj5Oj5c_RQPGzvqCt7E782ZF0X4ZQ2uC_c_wG6A4XI</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Akhtar, Othman Salim</creator><creator>Hillengass, Jens</creator><creator>Lipe, Brea</creator><creator>Figel, Sheila A.</creator><creator>Fenstermaker, Robert A.</creator><creator>Ciesielski, Michael J.</creator><creator>Lee, Kelvin P.</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy</title><author>Akhtar, Othman Salim ; Hillengass, Jens ; Lipe, Brea ; Figel, Sheila A. ; Fenstermaker, Robert A. ; Ciesielski, Michael J. ; Lee, Kelvin P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1857-37aef79593acbada2eb6f79dc659e475b5aab2e04835907340eb421f4a00a0d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akhtar, Othman Salim</creatorcontrib><creatorcontrib>Hillengass, Jens</creatorcontrib><creatorcontrib>Lipe, Brea</creatorcontrib><creatorcontrib>Figel, Sheila A.</creatorcontrib><creatorcontrib>Fenstermaker, Robert A.</creatorcontrib><creatorcontrib>Ciesielski, Michael J.</creatorcontrib><creatorcontrib>Lee, Kelvin P.</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akhtar, Othman Salim</au><au>Hillengass, Jens</au><au>Lipe, Brea</au><au>Figel, Sheila A.</au><au>Fenstermaker, Robert A.</au><au>Ciesielski, Michael J.</au><au>Lee, Kelvin P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>10170</spage><epage>10171</epage><pages>10170-10171</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-163597</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2022-11, Vol.140 (Supplement 1), p.10170-10171
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2022_163597
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T06%3A23%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Phase%20I%20Study%20of%20Safety,%20Tolerability%20and%20Immunological%20Effects%20of%20SVN53-67/M57-KLH%20in%20Patients%20with%20Multiple%20Myeloma%20Receiving%20Lenalidomide%20Maintenance%20Therapy&rft.jtitle=Blood&rft.au=Akhtar,%20Othman%20Salim&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=10170&rft.epage=10171&rft.pages=10170-10171&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-163597&rft_dat=%3Celsevier_cross%3ES0006497122061274%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122061274&rfr_iscdi=true